NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are commonly included in anti-HIV
drug regimens. However, HIV infected women who have previously taken the single dose NNRTI
nevirapine (SD NVP) for the prevention of mother-to-child transmission (MTCT) of HIV may not
respond as well to NNRTIs as women who have never taken NVP. Another class of anti-HIV drugs,
protease inhibitors (PIs), may be more effective for women who have previously taken NNRTIs.
This study will compare the effectiveness of NNRTI- and PI-based regimens in women who have
taken NVP for prevention of MTCT of HIV. This study will also compare regimens including an
NNRTI with regimens including a PI in women who have never taken NVP.
Phase:
Phase 3
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)